Logo Lanfrica
  • Home
  • Atlas
  • Insights
  • Docs
  • Sign in

© 2026 Lanfrica. All rights reserved. All copyrights of the resources shown on the Lanfrica website belong to the original copyright holders, unless explicitly stated otherwise.

Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk

Domain:

healthcare

Record type:

datasetpaper
Creator:
DarTyrBarJon
Editor:
ApoApo
Publisher:
Apo
Host:avatar
Funder: Funding details are provided in the Supplementary Material AbstractPolygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally-efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, “select and shrink for summary statistics” (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestry; 7,669 women of East Asian ancestry; 1,072 women of African ancestry, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestry. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38(95%CI:1.28–1.48,AUC:0.588) per unit standard deviation, in women of European ancestry; 1.14(95%CI:1.08–1.19,AUC:0.538) in women of East Asian ancestry; 1.38(95%CI:1.21-1.58,AUC:0.593) in women of African ancestry; hazard ratios of 1.37(95%CI:1.30–1.44,AUC:0.592) in BRCA1 pathogenic variant carriers and 1.51(95%CI:1.36-1.67,AUC:0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs.

Visit

doi.orgwww.repository.cam.ac.uk

Tags

Article/692/499/631/208/2489/631/208/721/45/43/45/61article

Similar

Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach.Improved polygenic risk prediction models for breast cancer subtypes in women of African ancestry.Multi-ethnic polygenic risk scores improve risk prediction in diverse populationsIdentification of novel epithelial ovarian cancer loci in women of African ancestry.BRCA1 and BRCA2 Risk Perceptions among African American Women at Increased Risk for Hereditary Breast-Ovarian CancerPredictors of Survival Outcomes After Primary Treatment of Epithelial Ovarian Cancer in Lagos, Nigeria

Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach.

Polygenic risk scores (PRSs) are useful for predicting breast cancer risk, but the prediction accura

Improved polygenic risk prediction models for breast cancer subtypes in women of African ancestry.

Polygenic risk score (PRS) models effectively predict breast cancer (BC) risk in European-ancestr

Multi-ethnic polygenic risk scores improve risk prediction in diverse populations

Abstract Methods for genetic risk prediction have been widely i

Identification of novel epithelial ovarian cancer loci in women of African ancestry.

Women of African ancestry have lower incidence of epithelial ovarian cancer (EOC) yet worse survival

BRCA1 and BRCA2 Risk Perceptions among African American Women at Increased Risk for Hereditary Breast-Ovarian Cancer

Objectives: To describe BRCA1 or BRCA2 (BRCA1/2) risk perceptions among African A

Predictors of Survival Outcomes After Primary Treatment of Epithelial Ovarian Cancer in Lagos, Nigeria

PURPOSE This study was designed to investigate the clinicopathologic predictors of progression-fre